Exdensur nucala competitors?

Which companies make drugs that compete with Nucala (exdensur)?

Nucala is the brand name for benralizumab, a treatment used for severe eosinophilic asthma. Competitors are other therapies for the same patient population (often patients with high blood eosinophils or severe uncontrolled asthma) and, in some cases, other biologics that target overlapping immune pathways.

What are the main competitor biologics to Nucala?

Key competitive options in severe eosinophilic asthma include:
- Dupixent (dupilumab) by Sanofi and Regeneron, which targets IL-4/IL-13 signaling.
- Fasenra (benralizumab) is the same molecule as Nucala (so it competes as an alternative branded product rather than a different mechanism).
- Tezspire (tezepelumab) by AstraZeneca, which targets thymic stromal lymphopoietin (TSLP), a pathway upstream of multiple inflammatory signals.
- Cinqair (reslizumab) by Teva, which targets IL-5.
- Other asthma biologics targeting IL-5 or IL-5 receptor pathways (depending on which geography and indication are being compared) can also be considered competitive alternatives.

How do the mechanisms differ—IL-5/IL-5R vs IL-4/IL-13 vs TSLP?

Even when drugs are used for similar real-world groups (severe asthma with eosinophils), their target differs:
- Benralizumab (Nucala) blocks the IL-5 receptor alpha chain on immune cells, reducing eosinophils.
- Reslizumab targets IL-5 directly.
- Dupilumab targets IL-4 and IL-13 signaling.
- Tezepelumab targets TSLP, which can affect multiple downstream inflammatory pathways, including eosinophilic inflammation.

These mechanism differences matter because they can influence which patients respond best and how clinicians choose among options.

Are there cheaper or lower-cost alternatives that still compete?

In many markets, the main “practical” competitors are other biologics, because they are the same therapeutic class for severe asthma. Whether a lower-cost option exists depends on pricing, rebates, payer coverage, and whether biosimilar or alternative branded products are available for the relevant mechanism in that country.

If you tell me your country and whether you mean “competitors by mechanism” or “competitors by market share/prescribing,” I can narrow the list.

Is “Exdensur” the same as Nucala, or a different drug?

I can’t verify “Exdensur” from the information provided in your question. If you meant a different product name (or a local brand name), share the active ingredient or spelling you’re using, and I’ll map competitors correctly to that specific drug.

Where can I check patents and competitive pipeline details?

For drug exclusivity and patent-related context, DrugPatentWatch.com can help track the legal landscape around specific biologics and related products. Use it when you want to understand when competitors might enter or how patent positions differ.
You can search DrugPatentWatch.com here: https://www.drugpatentwatch.com/

Sources

1. https://www.drugpatentwatch.com/